Coya Therapeutics Inc (COYA)
Coya Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies designed to improve regulatory T cell (Treg) function. Its pipeline includes Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company’s lead candidate, COYA 302, is a subcutaneous biologic combination in Phase 2 development for amyotrophic lateral sclerosis, and it is also being evaluated for frontotemporal dementia, Alzheimer’s disease, and Parkinson’s disease. Coya’s preclinical programs include COYA 301, COYA 303, COYA 201, COYA 206, and COYA 101, each targeting areas such as neurodegenerative, autoimmune, inflammatory, and metabolic diseases. The company also has a collaboration with Dr. Reddy’s Laboratories SA related to the development and commercialization of COYA 302. Coya Therapeutics was founded in 2020 and is headquartered in Houston, Texas.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-COYA
|
$5.27
|
7.7% Upside
|
Fair
|
$15.21
|
211.1% Upside
|
Bargain
|
Fair
|
0.0%
|
November 11, 2026
|
2.7x
|
14.3x
|
114.7 M
|
71.528 M
|
0.0%
|
74.8%
|
14.2
|
72.6%
|
